The American Society of Clinical Oncology is hoping to influence treatment decisions with a scorecard that determines the value of drugs based on benefit, toxicity and cost.

In an interview with BioCentury This Week television, ASCO CMO Richard Schilsky said the project is needed because the price of cancer drugs is becoming unsustainable, and in many cases benefits are not commensurate with their cost.